Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Trop Med Int Health ; 29(5): 434-445, 2024 May.
Article in English | MEDLINE | ID: mdl-38470004

ABSTRACT

OBJECTIVES: Treatment interruption is associated with poor tuberculosis (TB) treatment outcomes and increased drug resistance. To address the issue, we aimed to investigate the characteristics, predictors and consequences of treatment interruption. METHODS: We conducted a retrospective cohort study by retrieving 4 years (2018-2021) of TB patients' records at 10 public health clinics in Sarawak, Malaysia. Adult patients (≥18 years) with drug-susceptible TB were selected. Treatment interruption was defined as ≥2 weeks of cumulative interruption during treatment. The Chi-square test, Mann-Whitney U test, Kaplan-Meier and Cox proportional hazards regression were used to analyse the data, with p < 0.05 being considered statistically significant. RESULTS: Out of 2953 eligible patients, 475 (16.1%) experienced TB treatment interruption. Interruptions were most frequent during the intensive phase (46.9%, n = 223), with the greatest risk within the first 4 weeks of treatment. The median time to interruption was 2 weeks in the intensive phase and the cumulative interruption probability at the end of the intensive phase was 12.9%. Notably, treatment interruption occurred during both intensive and continuation phases for 144 patients (30.3%), while the remaining 108 (22.7%) experienced interruptions only during the continuation phase with a median time to interruption of 16 weeks. Three predictors were identified to increase the risk of treatment interruption: adverse drug reaction (aHR = 8.53, 95% Cl: 6.73-10.82), smoking (aHR = 2.67, 95% Cl: 2.03-3.53) and illicit drug use (aHR = 1.88, 95% Cl: 1.03-3.45). Conversely, underlying diabetes was associated with a reduced likelihood of treatment interruption (aHR = 0.72, 95% Cl: 0.58-0.90). Treatment interruption led to significant differences in treatment restarts (62.3% vs. 0.7%), changes in medications (47.8% vs. 4.9%), prolonged treatment duration (247 days [IQR = 105] vs. 194 days [IQR = 44.3]) and lower successful outcomes (86.5% vs. 99.9%). CONCLUSION: Understanding the temporal characteristics, predictors and negative consequences of treatment interruption can guide the development of time-relevant approaches to mitigate the problem.


Subject(s)
Antitubercular Agents , Humans , Retrospective Studies , Female , Male , Adult , Antitubercular Agents/therapeutic use , Antitubercular Agents/administration & dosage , Malaysia , Middle Aged , Tuberculosis/drug therapy , Medication Adherence/statistics & numerical data , Young Adult , Cohort Studies , Risk Factors , Treatment Outcome , Proportional Hazards Models , Treatment Interruption
2.
BMJ Glob Health ; 8(1)2023 01.
Article in English | MEDLINE | ID: mdl-36650014

ABSTRACT

INTRODUCTION: Tuberculosis (TB) treatment interruption remains a critical challenge leading to poor treatment outcomes. Two-thirds of global new TB cases are mostly contributed by Asian countries, prompting systematic analysis of predictors for treatment interruption due to the variable findings. METHODS: Articles published from 2012 to 2021 were searched through seven databases. Studies that established the relationship for risk factors of TB treatment interruption among adult Asian were included. Relevant articles were screened, extracted and appraised using Joanna Briggs Institute's checklists for cohort, case-control and cross-sectional study designs by three reviewers. Meta-analysis was performed using the random effect model in Review Manager software. The pooled prevalence and predictors of treatment interruption were expressed in ORs with 95% CIs; heterogeneity was assessed using the I2 statistic. The publication bias was visually inspected using the funnel plot. RESULTS: Fifty eligible studies (658 304 participants) from 17 Asian countries were included. The overall pooled prevalence of treatment interruption was 17% (95% CI 16% to 18%), the highest in Southern Asia (22% (95% CI 16% to 29%)), followed by Eastern Asia (18% (95% CI 16% to 20%)) and South East Asia (16% (95% CI 4% to 28%)). Seven predictors were identified to increase the risk of treatment interruption, namely, male gender (OR 1.38 (95% CI 1.26 to 1.51)), employment (OR 1.43 (95% CI 1.11 to 1.84)), alcohol intake (OR 2.24 (95% CI 1.58 to 3.18)), smoking (OR 2.74 (95% CI 1.98 to 3.78)), HIV-positive (OR 1.50 (95% CI 1.15 to 1.96)), adverse drug reactions (OR 2.01 (95% CI 1.20 to 3.34)) and previously treated cases (OR 1.77 (95% CI 1.39 to 2.26)). All predictors demonstrated substantial heterogeneity except employment and HIV status with no publication bias. CONCLUSION: The identification of predictors for TB treatment interruption enables strategised planning and collective intervention to be targeted at the high-risk groups to strengthen TB care and control in the Asia region.


Subject(s)
Tuberculosis , Adult , Humans , Male , Tuberculosis/drug therapy , Tuberculosis/epidemiology , Prevalence , Cross-Sectional Studies , Risk Factors , Asia/epidemiology
3.
J Pharm Policy Pract ; 15(1): 7, 2022 Jan 24.
Article in English | MEDLINE | ID: mdl-35073999

ABSTRACT

BACKGROUND: Delays in producing discharge prescriptions have hindered the provision of bedside dispensing services (BEDISC) that enable medication reconciliation and pharmaceutical intervention, which is an important element in transitional care medication safety. We aimed to assess the impact of early medication discharge planning on the delivery of BEDISC in terms of the rate of bedside dispensing, medication errors, and cost-saving from medication reconciliation by reusing patient's own medicines (POMs). METHODS: A pre-post intervention study was conducted at medical wards in a public tertiary hospital. During the intervention phase, a structured bedside dispensing process was delineated and conveyed to the doctors, nurses, and pharmacists. Regular verbal reminders were given to the doctors to prioritize discharge patients by producing the prescriptions once discharge decisions had been made and nurses to hand the prescriptions to ward pharmacists and not patients. Throughout the study, ward pharmacists were involved in medication reconciliation via screening of discharge prescriptions and reusing POMs, performed pharmaceutical interventions for any medication errors detected, and provided bedside dispensing with discharge counseling. Comparisons were made between bedside versus counter-dispensing at pre-post intervention phases using the chi-square test. RESULTS: A total of 1097 and 817 discharge prescriptions were dispensed in the pre-intervention and post-intervention phases, respectively. The bedside dispensing rate increased by 13.5% following remedial actions (p < 0.001). The number of prescriptions intervened due to detection of medication errors increased by 13.4% for bedside dispensing (p < 0.001) versus 4.7% for counter-dispensing (p = 0.002), post-intervention. Most medication errors fell under the category of inappropriate drug (44.5%), followed by inappropriate dose (12.8%). Reusing POMs resulted in cost-saving of MYR6,851.66 at pre-intervention and MYR7,032.98 at the post-intervention phase. Overall, the cost-saving from reusing POMs in both intervention phases was 52.7% (MYR13,884.64 out of the total MYR26.367.47), with the majority contributed by respiratory medications (40.2%) followed by cardiovascular (18%) and vitamins/minerals (17.5%). CONCLUSION: Pharmacist-coordinated early medication discharge planning has improved the delivery of bedside dispensing services, enhanced medication safety, and reduced medication costs.

4.
J Pharm Pract ; 35(3): 407-412, 2022 Jun.
Article in English | MEDLINE | ID: mdl-33433248

ABSTRACT

INTRODUCTION: Medication history assessment during hospital admissions is an important element in the medication reconciliation process. It ensures continuity of care and reduces medication errors. OBJECTIVES: This study aimed to determine the incidence of unintentional discrepancies (medication errors), types of medication errors with its potential severity of patient harm and acceptance rate of pharmaceutical care interventions. METHODS: A four-month cross-sectional study was conducted in the general medical wards of a tertiary hospital. All newly admitted patients with at least one prescription medication were recruited via purposive sampling. Medication history assessments were done by clinical pharmacists within 24 hours or as soon as possible after admission. Pharmacist-acquired medication histories were then compared with in-patient medication charts to detect discrepancies. Verification of the discrepancies, interventions, and assessment of the potential severity of patient harm resulting from medication errors were collaboratively carried out with the treating doctors. RESULTS: There were 990 medication discrepancies detected among 390 patients recruited in this study. One hundred and thirty-five (13.6%) medication errors were detected in 93 (23.8%) patients (1.45 errors per patient). These were mostly contributed by medication omissions (79.3%), followed by dosing errors (9.6%). Among these errors, 88.2% were considered "significant" or "serious" but none were "life-threatening." Most (83%) of the pharmaceutical interventions were accepted by the doctors. CONCLUSION: Medication history assessment by pharmacists proved vital in detecting medication errors, mostly medication omissions. Majority of the errors intervened by pharmacists were accepted by the doctors which prevented potential significant or serious patient harm.


Subject(s)
Medication Errors , Patient Admission , Cross-Sectional Studies , Hospitalization , Humans , Medication Errors/prevention & control , Medication Reconciliation/methods , Pharmacists
5.
Pharm. pract. (Granada, Internet) ; 13(3): 0-0, jul.-sept. 2015. tab, ilus
Article in English | IBECS | ID: ibc-140792

ABSTRACT

Background: Proton-pump inhibitors (PPI) and histamine-2 receptor antagonists (H2RA) are common acid suppressants used in gastrointestinal disorders. The trend of usage in Malaysia has changed from predominantly H2RA to PPI from 2007 to 2008, 3.46 versus 2.87 and 2.99 versus 3.24 DDD (Defined Daily Dose)/1000 population/day respectively. This raises concerns as PPI overutilization amounts to higher cost expenditure and are associated with various untoward consequences such as Clostridium difficile-associated diarrhea, pneumonia, and osteoporosis. Objectives: To evaluate the indication of acid suppression therapy (AST) and to look for predictors associated with the prophylactic use of PPI as compared to H2RA. Methods: Data collection was conducted via a standardized surveillance form over a 2-month period in the general medical wards of Sarawak General Hospital. All patients who received at least one dose of PPI or H2RA in any dosage form were included in the study. Appropriateness of prophylaxis was determined using current available guidelines. Selected risk factors were analysed using simple logistic regression to look for predictors associated with the choice of PPI in prophylactic AST. Results: Out of 212 cases in the present cohort, about three quarters (75.5%, n=160) of acid suppressants were given as prophylaxis. Over half of these did not have appropriate indications for prophylactic AST (58.1%, n=93). Among all cases given prophylactic AST, 75.0% (n=120) of them were given PPI. Renal insufficiency was identified as the only predictor associated with the use of prophylactic PPI in preference to H2RA (OR=2.86, 95%CI 1.21:6.72, p=0.011). Conclusion: Inappropriate prophylactic AST is a major concern and may even be underestimated due to the lack of appropriate guidelines. More data is required to guide the selection between PPI and H2RA, specifically the more cost-effective use of H2RA in patients with lower gastrointestinal risk or in whom PPI has no clear advantage (AU)


Antecedentes: Los inhibidores de la bomba de protones (PPI) y los antagonistas de los receptores de histamina-2 (H2RA) son antiácidos comunes que se usan en desordenes gastrointestinales. La tendencia de uso en Malasia ha cambiado de la predominancia de H2RA a PPI entre 2007 y 2008 de 3,46 vs. 2,87 y 2,99 vs. 3,24 DDD (Dosis Diarias Definida)/1000 habitantes/día, respectivamente. Esto preocupa ya que la sobreutilización de PPI produce mayores costes y están asociados a varias consecuencias indeseadas como diarrea asociada a Clostridium difficile, neumonía, y osteoporosis. Objetivos: Evaluar la indicación del tratamiento de supresión ácida (AST) y buscar predictores asociados con el uso de PPI comparados con H2RA. Métodos: Se recogieron datos mediante un formulario de vigilancia estandarizado durante 2 meses en los servicios de medicina heneral del Hospital General de Sarawak. Todos los pacientes que recibieron, al menos una dosis de PPI o de H2RA en cualquier forma fueron incluidos en el estudio. La adecuación del tratamiento fue determinada usando las guías disponibles actualmente. Se analizaron los factores de riesgo usando una regresión logística simple para buscar predictores asociados con la elección de PPI en AST profiláctica. Resultados: De los 200 casos presentes en la cohorte, cerca de tres cuartos (75,5; n=160) de los antiácidos fueron usado como profilácticos. Más de la mitad de ellos no tenían una indicación apropiada para AST profiláctica (58,1%, n=93). Entre todos los casos con AST profiláctica, el 75,0% (n=120) eran PPI. La insuficiencia renal fue el factor asociado con el uso de profilaxis con PPI en preferencia a los H2RA (OR=2,86; 95%CI 1,21:6,72, p=0,011). Conclusión: La AST profiláctica inadecuada es una gran problema y podría estar subestimada debido a la ausencia de guías apropiadas. Se requieren más datos para guiar la selección entre PPI y H2RA, específicamente el uso más coste-efectivo de los H2RA en pacientes con riesgo gastrointestinal bajo, o en los que no hay una clara ventaja de los PPI (AU)


Subject(s)
Female , Male , Middle Aged , Humans , Suppression/trends , Proton Pumps/therapeutic use , Histamine H2 Antagonists/metabolism , Histamine H2 Antagonists/therapeutic use , Risk Factors , Malaysia/epidemiology , Antacids/therapeutic use , Diarrhea/complications , Diarrhea/economics , Clostridioides difficile/isolation & purification , Pneumonia/complications , Osteoporosis/complications , Logistic Models , Cohort Studies
6.
J Infect Dev Ctries ; 8(2): 193-201, 2014 Feb 13.
Article in English | MEDLINE | ID: mdl-24518629

ABSTRACT

INTRODUCTION: The widespread and inappropriate use of broad-spectrum antibiotics in surgical prophylaxis has led to reduced treatment efficacy, increased healthcare costs, and antibiotic resistance. This study aimed to explore the adherence of antibiotic usage in surgical prophylaxis to the national antibiotic guideline and the incidences of surgical site infection (SSI). METHODOLOGY: A three-month prospective observational study has been conducted in the surgical wards of Sarawak General Hospital (SGH) using a standardized surveillance form. Each patient was reviewed for up to 30 days post-operatively to determine the occurrence of SSI. RESULTS: A total of 87 patients were included within the study period. The majority of the cases were clean-contaminated wounds (60.9%). Most were hepatobiliary cases (37.9%), followed by colorectal cases (19.5%). The most preferred antibiotic used was cefoperazone (63.2%). The choices of antibiotics in 78.2% of the cases were consistent with the guideline. Around 80% of prophylactic antibiotics were given within one hour before operation and 27.6% were omitted from intraoperative re-dosing. Prophylactic antibiotics were discontinued within 24 hours post-operatively in 77% of the cases. Of those continued for > 24 hours, the majority (60%) were administered for unknown reasons. SSI was documented in 13.8% of the total cases studied. However, there was no significant association between choices of antibiotics and timing of surgical prophylaxis with SSI (p = 0.299 and p = 0.258 respectively). CONCLUSION: Overall guideline adherence rate was more than 70%. Areas of non-concordance to the guideline require further investigation.


Subject(s)
Antibiotic Prophylaxis/methods , Surgical Wound Infection/epidemiology , Surgical Wound Infection/prevention & control , Tertiary Care Centers , Adult , Aged , Anti-Bacterial Agents/therapeutic use , Female , Guideline Adherence , Humans , Incidence , Malaysia/epidemiology , Male , Middle Aged , Prospective Studies , Risk Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...